谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

Eijiro Shimada,Makoto Endo,Yoshihiro Matsumoto,Kenji Tsuchihashi,Mamoru Ito,Hitoshi Kusaba,Akira Nabeshima, Tomoya Nawata,Akira Maekawa,Tomoya Matsunobu,Nokitaka Setsu,Toshifumi Fujiwara,Keiichiro Iida,Makoto Nakagawa,Takeshi Hirose,Masaya Kanahori,Ryunosuke Oyama,Taichi Isobe,Hiroshi Ariyama,Kenichi Kohashi,Hidetaka Yamamoto,Yoshinao Oda,Yukihide Iwamoto,Koichi Akashi,Eishi Baba,Yasuharu Nakashima

JOURNAL OF CLINICAL MEDICINE（2021）

引用 4|浏览28
暂无评分
关键词
soft tissue sarcoma,chemotherapy,pazopanib,trabectedin,eribulin,prognosis,biomarker,peripheral immune-related marker,neutrophil to lymphocyte ratio,platelet to lymphocyte ratio
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要